Notable Labs

Notable Labs is a next-generation translational drug discovery company that uses a clinically validated, automated compound sensitivity platform to identify and advance novel therapeutic candidates at a fraction of the cost and time of the traditional drug development process.

Ex vivo drug sensitivity platform accurately predicts clinical trial outcomes
Notable screens thousands of drugs to identify personalized drug combinations for cancer patients
Collaboration with Stanford shows platform is 84% accurate in predicting responses in patients
Partnerships with 5 large pharma's and12+ biotechs

MATT DE SILVA
Co-Founder & CEO
Co-Founder & CEO, Notable Labs
30 Under 30 2017: Healthcare - Forbes
Clarium Capital Management, Analyst - Trading & Research
Cornell University, B.S. Applied Economics & Management

PETE QUINZIO
Co-Founder
Co-Founder, Notable Labs
Leukemia & Lymphoma Society 'Man of the Year' in 2018
Tesla Motors, Analyst
Morgan Stanley, Investment Banking Analyst
Princeton University

DIANE HEISER
Scientific Co-founder & CTO
Scientific Co-Founder & Chief Technology Officer, Notable Labs
Stanford University School of Medicine, Postdoctoral Researcher
The Johns Hopkins School of Medicine, Ph.D. Cellular & Molecular Medicine
Princeton University, B.A. Molecular Biology

SCOTT PATTERSON
VP, Engineering
VP, Engineering, Notable Labs
VP, Engineering, Counsyl
Founding software engineer, Counsyl
Director of Engineering, Counsyl
The Johns Hopkins University, M.A. Biophysics

MICHAEL HOROWITZ
COO & General Counsel
Chief Operating Officer & General Counsel, Notable Labs
Board Member, Altus BioPharma / i2 Pharmaceuticals
COO & GC, Sea Lane Biotechnologies
Associate, WSGR
Duke Law School, JD
Duke University, B.A.